Updates are available Correction dated 2025-12-08

Article History

Received: 27 June 2025

Revised: 27 June 2025

Accepted: 27 July 2025

First Online: 19 August 2025

Change Date: 9 December 2025

Change Type: Update

Change Details: The original online version of this article was revised to update the table 1.

Change Date: 8 December 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12185-025-04107-9

Declarations

:

: SI 1) has received per diem, including speaking fees, from Janssen Pharmaceutical, Bristol Myers Squibb, Sanofi, Takeda Pharmaceuticals, and Ono Pharmaceutical; has received research funding from Janssen Pharmaceutical, Bristol Myers Squibb, Sanofi, Takeda Pharmaceuticals, Ono Pharmaceutical, Pfizer, Novartis Pharma, Daiichi Sankyo, Celgene, Kyowa Kirin, Amgen, AbbVie, GlaxoSmithKline, and Alexion Pharmaceuticals; and has received scholarship or grant donations from Chugai Pharmaceutical. SI 2) has received per diem, including speaking fees, from Bristol Myers Squibb, Janssen Pharmaceutical, Takeda Pharmaceuticals, Sanofi, Ono Pharmaceutical, and Chugai Pharmaceutical; has received research funding from Meiji Seika Pharma, Kissei Pharmaceutical, Sanofi, AbbVie, Bristol Myers Squibb, Janssen Pharmaceutical, Parexel International, CMIC, and ICON Clinical Research; and has received scholarship or grant donations from Chugai Pharmaceutical, Asahi Kasei Pharma, Eisai, Bayer Yakuhin, Kyowa Kirin, Shionogi, and Ono Pharmaceutical. KS has received per diem, including speaking fees, from Ono Pharmaceutical, Janssen Pharmaceutical, Sanofi, Bristol Myers Squibb, and Celgene; and has received research funding from Ono Pharmaceutical, MSD, Celgene, AbbVie, Takeda Pharmaceuticals, Sanofi, Janssen Pharmaceutical, GlaxoSmithKline, Chugai Pharmaceutical, Novartis Pharma, Otsuka Pharmaceutical, Bristol Myers Squibb, Pfizer, Kyowa Kirin, Parexel International, Astellas Pharma, and Amgen. HT serves as a director or advisor for SRL; has received per diem, including speaking fees, from Janssen Pharmaceutical, Sanofi, Ono Pharmaceutical, and Bristol Myers Squibb; and has received research funding from Bristol Myers Squibb. NT has received per diem, including speaking fees, from Janssen Pharmaceutical and Sanofi; and has received research funding from Sanofi. NH has received research funding from Otsuka Pharmaceutical and Chugai Pharmaceutical; and has received scholarship or grant donations from Chugai Pharmaceutical, Kyowa Kirin, Shionogi, Asahi Kasei Pharma, Otsuka Pharmaceutical, Nippon Shinyaku, Eisai, Takeda Pharmaceuticals, Teijin Pharma, Ono Pharmaceutical, and Mochida Pharmaceutical. HM has no conflicts of interest to report.